OBJECTIVE: The objective of this study was to identify magnetic resonance imaging (MRI) characteristics of fibrocystic change (FCC) of the breast. MATERIALS AND METHODS: Fourteen patients with a histopathologic diagnosis of solitary FCC of the breast underwent x-ray mammography and MRI of the breast. Three experienced breast imaging radiologists retrospectively reviewed the MRI findings and categorized the lesions on morphologic and kinetic criteria according to the ACR BI-RADS-MRI Lexicon. RESULTS: The most striking morphologic feature of fibrocystic change was nonmass-like regional enhancement found in 6 of 14 (43%) FCC lesions. Based on morphologic criteria alone, 12 of 14 (86%) lesions were correctly classified as benign. According to analysis of the time-intensity curves, 10 of 14 (71%) FCC lesions were correctly classified as benign. CONCLUSION: Although FCC has a wide spectrum of morphologic and kinetic features on MRI, it most often presents as a mass or a nonmass-like regional enhancing lesion with benign enhancement kinetics.
OBJECTIVE: The objective of this study was to identify magnetic resonance imaging (MRI) characteristics of fibrocystic change (FCC) of the breast. MATERIALS AND METHODS: Fourteen patients with a histopathologic diagnosis of solitary FCC of the breast underwent x-ray mammography and MRI of the breast. Three experienced breast imaging radiologists retrospectively reviewed the MRI findings and categorized the lesions on morphologic and kinetic criteria according to the ACR BI-RADS-MRI Lexicon. RESULTS: The most striking morphologic feature of fibrocystic change was nonmass-like regional enhancement found in 6 of 14 (43%) FCC lesions. Based on morphologic criteria alone, 12 of 14 (86%) lesions were correctly classified as benign. According to analysis of the time-intensity curves, 10 of 14 (71%) FCC lesions were correctly classified as benign. CONCLUSION: Although FCC has a wide spectrum of morphologic and kinetic features on MRI, it most often presents as a mass or a nonmass-like regional enhancing lesion with benign enhancement kinetics.
Authors: Thomas Schlossbauer; Gerda Leinsinger; Axel Wismuller; Oliver Lange; Michael Scherr; Anke Meyer-Baese; Maximilian Reiser Journal: Invest Radiol Date: 2008-01 Impact factor: 6.016
Authors: Sanaz A Jansen; Xiaobing Fan; Gregory S Karczmar; Hiroyuki Abe; Robert A Schmidt; Maryellen Giger; Gillian M Newstead Journal: Med Phys Date: 2008-07 Impact factor: 4.071
Authors: Zorica C Milosevic; Mirjan M Nadrljanski; Zorka M Milovanovic; Nina Z Gusic; Slavko S Vucicevic; Olga S Radulovic Journal: Radiol Oncol Date: 2017-05-07 Impact factor: 2.991